| scholarly article | Q13442814 |
| P2093 | author name string | Munir Boodhwani | |
| Frank W Sellke | |||
| Shu-Hua Xu | |||
| Kamal R Khabbaz | |||
| Neel R Sodha | |||
| Richard T Clements | |||
| P2860 | cites work | Angiostatin binds ATP synthase on the surface of human endothelial cells | Q22009028 |
| Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation | Q24290939 | ||
| Endostatin: an endogenous inhibitor of angiogenesis and tumor growth | Q24315369 | ||
| Interaction of endostatin with integrins implicated in angiogenesis | Q24545535 | ||
| Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin | Q24601633 | ||
| Tissue inhibitors of metalloproteinases: evolution, structure and function | Q28138083 | ||
| Role of angiogenesis in tumor growth and metastasis | Q29614309 | ||
| Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma | Q29615947 | ||
| In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia | Q33275911 | ||
| Antiangiogenesis signals by endostatin. | Q33941743 | ||
| Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. | Q34130059 | ||
| Clinical translation of angiogenesis inhibitors | Q34152769 | ||
| Endostatin's antiangiogenic signaling network | Q34306081 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| Endostatin: the logic of antiangiogenic therapy | Q36153734 | ||
| Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated | Q36226300 | ||
| Growth factors for therapeutic angiogenesis in peripheral arterial disease | Q36925173 | ||
| Insulin treatment enhances the myocardial angiogenic response in diabetes | Q37180237 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial | Q38522489 | ||
| Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb | Q39425647 | ||
| Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease | Q39465201 | ||
| Protein kinase B inhibits endostatin-induced apoptosis in HUVECs | Q40319101 | ||
| Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. | Q42832012 | ||
| Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial | Q43619839 | ||
| Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells | Q43714114 | ||
| Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors | Q43982335 | ||
| Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication | Q44123397 | ||
| Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin | Q44891103 | ||
| Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia | Q45858618 | ||
| Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia | Q45886388 | ||
| Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. | Q46464366 | ||
| Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress | Q46904947 | ||
| Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease | Q47743568 | ||
| An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. | Q51186989 | ||
| Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. | Q53617689 | ||
| An interspecies comparison of normal levels of glycosylated hemoglobin and glycosylated albumin. | Q54067080 | ||
| Interaction of endostatin with integrins implicated in angiogenesis | Q56591884 | ||
| Lower-extremity amputation in people with diabetes. Epidemiology and prevention | Q64129851 | ||
| Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial | Q64377629 | ||
| Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation | Q64377911 | ||
| Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial | Q73069742 | ||
| Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial | Q74139377 | ||
| Endostatin induces endothelial cell apoptosis | Q77335987 | ||
| Effect of diabetes mellitus on formation of coronary collateral vessels | Q77393455 | ||
| Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes | Q78290470 | ||
| Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study | Q80048093 | ||
| Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease | Q81667234 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 463-470 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Archives of Surgery | Q15764793 |
| P1476 | title | Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients | |
| P478 | volume | 143 |
| Q34009401 | Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome |
| Q47667458 | Endostatin: a promising biomarker in the cardiovascular continuum? |
| Q38644013 | Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. |
| Q30430438 | Gene therapy from the perspective of systems biology |
| Q36820684 | Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles |
| Q48130652 | Neuropeptide Y improves myocardial perfusion and function in a swine model of hypercholesterolemia and chronic myocardial ischemia |
| Q36143074 | Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia |
| Q38629583 | Regulation of skeletal muscle capillary growth in exercise and disease |
Search more.